Related Experiment Videos
Cyclosporin in localized and systemic scleroderma--a clinical study.
Dermatologica
|January 1, 1990
Summary
Ciclosporin (CS) showed clinical improvement in four scleroderma patients, aiding skin sclerosis and ulcer healing. However, one patient experienced hypertension and renal dysfunction, necessitating careful patient selection and monitoring.
Area of Science:
- Immunology
- Dermatology
- Nephrology
Background:
- Scleroderma is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues.
- Current treatments for scleroderma aim to manage symptoms and slow disease progression, with limited options for significant reversal of fibrosis.
Observation:
- Five patients with scleroderma (4 systemic, 1 localized) received treatment with ciclosporin (CS) at daily doses ranging from 2.2 to 5.6 mg/kg for 3–26 months.
- Clinical improvements were noted in four patients, including regression of skin sclerosis and inflammation, healing of digital and leg ulcers, and enhanced joint mobility.
Findings:
- Ciclosporin (CS) demonstrated efficacy in improving key clinical manifestations of scleroderma in a majority of treated patients.
- A significant adverse event was observed in one patient with rapidly progressive systemic scleroderma, who developed arterial hypertension and renal dysfunction following short-term, low-dose CS therapy.
Implications:
- Ciclosporin (CS) may represent a potential therapeutic option for managing scleroderma symptoms, particularly cutaneous manifestations and ulcerations.
- The risk of serious adverse effects, including hypertension and renal dysfunction, highlights the critical need for careful patient selection and rigorous monitoring during CS treatment for scleroderma.